CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline
CStone Pharmaceuticals (HKG: 2616) reported 2025 financial results, with annual sales declining 33.8% YoY to...
Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) announced clinical trial approval from China’s National...
Huadong Medicine’s HDM2024 Wins NMPA Approval – EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors
Huadong Medicine Co., Ltd. (SHE: 000963) announced clinical trial approval from China’s National Medical Products...
Biocytogen’s NEOK002 Wins FDA Approval for Phase I – EGFR/MUC1 Bispecific ADC Targets Solid Tumors
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced that NEOK Bio, Inc., its...
Joincare Pharma’s JKN2404 Wins NMPA Approval for Asthma Trial – Next-Gen Inhaled Corticosteroid Targets Improved Safety Profile
Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that JKN2404 inhalation suspension, a Category...
Grand Pharma 2025 Revenue HKD 12.28B – Innovative Products Hit 50% of Sales, Radiopharma Soars 61%
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) reported 2025 financial results, with revenue rising 5.5%...
Pulmongene’s PMG1015 Wins FDA Fast Track Designation – First-in-Class AREG Antibody Targets Idiopathic Pulmonary Fibrosis
Pulmongene (Beijing) Ltd. announced that PMG1015 received Fast Track Designation (FTD) from the U.S. Food...
China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years
China’s State Council issued “Opinions on Accelerating the Establishment of a Long-Term Care Insurance System”,...
Simcere Pharma 2025 Revenue RMB 7.7B – Innovative Drugs Drive 28% Growth, Profit Surges 86%
Simcere Pharmaceutical Group (HKG: 2096) reported 2025 financial results, with revenue rising 16.5% YoY to...
GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market
GlaxoSmithKline (GSK; NYSE: GSK) formed a strategic alliance with SPH Keyuan Trade, a China pharmaceutical...
Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) announced National Medical Products Administration (NMPA) marketing approval for...
Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%
Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR...
United Laboratories Novo Nordisk Report Positive Phase II Data for UBT251 – Triple GLP-1/GIP/GCG Agonist Achieves 19.7% Weight Los
Partners United Laboratories International Holdings Ltd (HKG: 3933) and Novo Nordisk (NYSE: NVO) announced positive...
Ascentage Pharma 2025 Revenue RMB 574M – Olverembatinib NRDL Inclusion Drives 81% Growth, Lisaftoclax Launches
Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) reported 2025 financial results, with revenue declining...
MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia
Merck & Co., Inc. (MSD; NYSE: MRK) announced a definitive agreement to acquire Terns Pharmaceuticals,...
Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification
Daiichi Sankyo Co., Ltd. (TYO: 4568) announced a strategic partnership with Tempus AI, Inc., a...
Hengrui Pharma 2025 Revenue RMB 31.6B – Innovative Drugs Drive 58% of Sales, Out-Licensing Hits RMB 3.4B
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) reported 2025 annual results, with operating...
Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic partnership with SHL Medical, a Switzerland-based...
XtalPi Achieves First Profitability – AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M
QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., reported 2025 financial results, achieving first annual...
Everest Medicines Revenue Surges 142% to RMB 1.7B – Nefecon Becomes First Non-Oncology Drug to Hit RMB 1B in First NRDL Year
Everest Medicines (HKG: 1952) reported 2024 financial results, with revenue skyrocketing 142% YoY to RMB...